BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 27
• 28
• 29
• 30

• Genetown

  Fractyl Presents New Revita DMR Liver Data In Type 2 Diabetes At American Association for Study of Liver Diseases 2016

  November 11, 2016

   · 

  4 min read
• Drug Development

  Biothera Preclinical Data Further Validate Mechanism Of Its Phase II Cancer Immunotherapy, Imprime PGG

  November 11, 2016

   · 

  3 min read
• FDA

  Janssen-Cilag International NV Release: European Commission (EC) Approves STELARA (Ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn’s Disease

  November 11, 2016

   · 

  11 min read
• Drug Development

  Wilson Therapeutics Presents Updated Preliminary Clinical Data On WTX101 At The American Association for Study of Liver Diseases Liver Meeting

  November 11, 2016

   · 

  6 min read
• Business

  Imprimis Signs Agreement With Specialty Pharmacy Division Of One Of The Nation’s Largest Pharmacy Benefit Managers

  November 11, 2016

   · 

  5 min read
• BioMidwest

  Genomenon Completes $1.8 Million Extended Seed Financing Round

  November 11, 2016

   · 

  2 min read
• Drug Development

  Enanta Pharmaceuticals, Inc. Announces New Data On FXR Agonist EDP-305 For Non-Alcoholic Steatohepatitis (NASH) At The Liver Meeting 2016

  November 11, 2016

   · 

  8 min read
• Drug Development

  ImmunoGen To Present Preclinical Data Highlighting Potential Of Combining Mirvetuximab Soravtansine With An Immune Checkpoint Inhibitor At SITC 2016 Annual Meeting

  November 11, 2016

   · 

  4 min read
• Business

  Perrigo Announces Appointment Of Two New Independent Directors To Board

  November 11, 2016

   · 

  4 min read
• Drug Development

  Enanta Pharmaceuticals, Inc. Announces Eight Weeks Of Treatment With AbbVie’s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates Across All Major Genotypes Of Chronic Hepatitis C

  November 11, 2016

   · 

  7 min read